Reza Ghanian, MD
Internal Medicine · Carson, CANPI 1639151350
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Johnson & Johnson at 46.6% of the total. Reporting peaked in 2021 at $448 and has fallen 82.9% since, to $77 in 2025.
Across 78 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$781
- Novo Nordisk$141
- AbbVie$137
- Abbott$78
- Lilly USA, LLC$77
- Dexcom, Inc.$71
- plus $391 from 14 others
What the payments were for
- Food & beverage$1,675100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 34 | $781 |
| Novo Nordisk | 7 | $141 |
| AbbVie | 6 | $137 |
| Abbott | 3 | $78 |
| Lilly USA, LLC | 4 | $77 |
| Dexcom, Inc. | 3 | $71 |
| Novartis | 3 | $62 |
| Bayer | 3 | $49 |
| AstraZeneca(2 entities) | 2 | $41 |
| GSK | 2 | $39 |
| Merck | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Seqirus USA Inc | 1 | $18 |
| Eisai Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $13 |
How this compares
$1,675 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 385 | $123,603 |
| JanuviaSitagliptin Phosphate | 130 | $90,919 |
| JardianceEmpagliflozin | 83 | $39,682 |
| EntrestoSacubitril/Valsartan | 51 | $26,359 |
| XareltoRivaroxaban | 65 | $26,186 |
| FarxigaDapagliflozin Propanediol | 29 | $18,381 |
| MounjaroTirzepatide | 12 | $17,773 |
| OzempicSemaglutide | 14 | $16,641 |
| SantylCollagenase Clostridium Hist. | 14 | $15,964 |
| TradjentaLinagliptin | 44 | $11,731 |
| Atorvastatin Calcium | 749 | $8,520 |
| LinzessLinaclotide | 13 | $7,426 |
| Permethrin | 123 | $6,204 |
| VascepaIcosapent Ethyl | 11 | $5,257 |
| HumalogInsulin Lispro | 71 | $5,189 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $31 | $90,919130 claims |
| Boehringer IngelheimJardiance, Tradjenta | $22 | $51,413127 claims |
| NovartisEntresto | $62 | $26,35951 claims |
| Johnson & JohnsonXarelto | $781 | $26,18665 claims |
| Lilly USA, LLCMounjaro, Humalog | $77 | $22,96183 claims |
| AstraZenecaFarxiga, Brilinta | $41 | $22,13051 claims |
| Novo NordiskOzempic | $141 | $16,64114 claims |
| AbbVieLinzess | $137 | $7,42613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Carson
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.